Medicenna Therapeutics Corp.MDNA.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · medicenna.com
Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company developing IL-2, IL-4, and IL-13 Superkines and bi-functional Superkines for the treatment of cancer and autoimmune diseases. The company's lead program, MDNA55, is an IL-4 receptor-targeted immunotherapy in clinical development for recurrent glioblastoma multiforme. Medicenna is headquartered in Toronto, Ontario.
Key ratios
ROA
-90.1%TTM
2026
-76.1%2025
-53.7%2024
-42.0%2023
-34.0%
ROE
-227.6%TTM
2026
-170.6%2025
-97.2%2024
-146.9%2023
-39.9%
Recent news
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at SNO 2026 Annual Meeting
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
Track MDNA.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer